CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Sell
45
OPRX Quote, Financials, Valuation and Earnings
Last price:
$9.49
Seasonality move
:
8.73%
Day range:
$9.12 - $9.73
52-week range:
$3.78 - $14.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.85x
P/B ratio:
1.47x
Volume:
145.5K
Avg. volume:
226.8K
1-year change:
-12.15%
Market cap:
$172.5M
Revenue:
$92.1M
EPS (TTM):
-$1.10
Analysts' Opinion
-
Consensus RatingOptimizeRx has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.83, OptimizeRx has an estimated upside of 16.11% from its current price of $9.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $9.33.
Fair Value
-
According to the consensus of 5 analysts, OptimizeRx has 16.11% upside to fair value with a price target of $10.83 per share.
OPRX vs. S&P 500
-
Over the past 5 trading days, OptimizeRx has overperformed the S&P 500 by 1.58% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
OptimizeRx does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OptimizeRx has grown year-over-year revenues for 6 quarters straight. In the most recent quarter OptimizeRx reported revenues of $32.3M.
Earnings Growth
-
OptimizeRx earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter OptimizeRx reported earnings per share of --.
Enterprise value:
192M
EV / Invested capital:
--
Price / LTM sales:
1.85x
EV / EBIT:
--
EV / Revenue:
2.08x
PEG ratio (5yr expected):
-1.08x
EV / Free cash flow:
43.24x
Price / Operating cash flow:
38.45x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$59.4M
Return On Assets:
-11.57%
Net Income Margin (TTM):
-21.83%
Return On Equity:
-16.71%
Return On Invested Capital:
-12.93%
Operating Margin:
11.25%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $62.5M | $71.5M | $92.1M | $28.4M | $32.3M | |
| Gross Profit | $39M | $42.9M | $59.4M | $17.8M | $22M | |
| Operating Income | -$12.3M | -$17.5M | -$6.2M | -$2M | $3.6M | |
| EBITDA | -$10.3M | -$21.3M | -$8.9M | -$9.3M | $4.9M | |
| Diluted EPS | -$0.63 | -$1.02 | -$1.10 | -$0.24 | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.9M | $115.1M | $98.6M | $54.3M | $54M | |
| Total Assets | $60.3M | $141M | $134.7M | $183.4M | $171.2M | |
| Current Liabilities | $10M | $9.4M | $8.4M | $17.9M | $18.7M | |
| Total Liabilities | $10.4M | $9.6M | $8.5M | $56.8M | $54.2M | |
| Total Equity | $50M | $131.4M | $126.1M | $126.6M | $117M | |
| Total Debt | -- | -- | -- | $36.2M | $32.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $10.7M | -$7.2M | $4.9M | -$6.3M | $198K | |
| Cash From Investing | -$58.2M | -$25.3M | -$450K | -$26M | -$120K | |
| Cash From Financing | -$19M | $28.2M | -$4.9M | $36.2M | -$2.8M | |
| Free Cash Flow | $10.4M | -$8.1M | $4.4M | -$5.5M | $78K | |
OPRX
Sector
Market Cap
$172.5M
$34.5M
Price % of 52-Week High
66.03%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
-12.15%
-42.08%
Beta (5-Year)
1.283
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$9.29
200-day SMA
Buy
Level
$6.87
Bollinger Bands (100)
Buy
Level
4.9 - 8.2
Chaikin Money Flow
Buy
Level
17M
20-day SMA
Buy
Level
$8.65
Relative Strength Index (RSI14)
Buy
Level
60.26
ADX Line
Buy
Level
26.81
Williams %R
Neutral
Level
-42.3387
50-day SMA
Buy
Level
$7.69
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
29.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8341)
Buy
CA Score
(Annual)
Level (0.2606)
Buy
Beneish M-Score
(Annual)
Level (-3.1112)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.7177)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Stock Forecast FAQ
In the current month, OPRX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The OPRX average analyst price target in the past 3 months is $10.83.
-
Where Will OptimizeRx Stock Be In 1 Year?
According to analysts, the consensus estimate is that OptimizeRx share price will rise to $10.83 per share over the next 12 months.
-
What Do Analysts Say About OptimizeRx?
Analysts are divided on their view about OptimizeRx share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OptimizeRx is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is OptimizeRx's Price Target?
The price target for OptimizeRx over the next 1-year time period is forecast to be $10.83 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is OPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OptimizeRx is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OPRX?
You can purchase shares of OptimizeRx via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OptimizeRx shares.
-
What Is The OptimizeRx Share Price Today?
OptimizeRx was last trading at $9.49 per share. This represents the most recent stock quote for OptimizeRx. Yesterday, OptimizeRx closed at $9.33 per share.
-
How To Buy OptimizeRx Stock Online?
In order to purchase OptimizeRx stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
